Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis

Inclusion Criteria: * Adult, post-menarchal, pre-menopausal women aged 18 years or older * Diagnosis of VVC, defined as having a white or creamy vaginal discharge plus the following findings: 1. At least 2 of the following signs and symptoms of VVC that are characterized as at least moderate: itching, burning, irritation, edema, redness, or excoriation. 2. Potassium hydroxide (KOH) or saline preparation from the inflamed vaginal mucosa or secretions revealing yeast forms (hyphae or pseudohyphae) or budding yeasts. * Having decisional capacity and providing written informed consent * Negative urine pregnancy test at screening * Refrain from using any intravaginal products (i.e., contraceptive creams, gels, foams, sponges, lubricants, or tampons, etc.) during the study period * Refrain from sexual intercourse or use a condom until Day 7 * Signed informed consent and willing and able to comply with all study requirements Exclusion Criteria: * Patients with known or apparent signs of other infectious causes of VVC (BV, Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis, Herpes simplex, or human papillomavirus) at screening * Patients who are pregnant or breastfeeding * Patients who were treated for VVC within the past 14 days * Patients who are currently receiving antifungal therapy unrelated to VVC or has taken antifungal therapy within the past 14 days * Patients who have used pH-modifying vaginal products within the last 14 days * Patients who have received an investigational drug in a clinical investigation within 30 days prior to screening * Known/previous allergy or hypersensitivity to any product constituent or fluconazole * Any medical condition that in the Investigator's judgments would make the patient unsuitable for inclusion